I placebokontrollerede kliniske forsøg svarede den samlede forekomst af malignitet (hvoraf størstedelen var non- melanom hudkræft) for patienter behandlet med Raptiva til den for patienter, som fik placebo.
In placebo controlled clinical trials, the overall incidences of malignancy (the majority of which were non-melanoma skin cancers) were similar in Raptiva-treated patients and in placebo-treated patients.